Acurx Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a 4.99% beneficial ownership stake in Acurx Pharmaceuticals, Inc.
NASDAQ
Armistice Capital and Steven Boyd have disclosed a passive 8.7% beneficial ownership stake in Acurx Pharmaceuticals, Inc. common stock.